Navigation Links
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
Date:9/25/2008

LAUSANNE, Switzerland, September 25 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl(R) (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Once approved, Decapeptyl(R) 6-month formulation will be marketed by Debiopharm's partners, such as Ipsen in most European Union countries.

"This submission in Europe of our first 6-month-formulation for the treatment of prostate cancer is another demonstration of Debiopharm's commitment to supporting and enhancing the life of cancer patients. With an injection every 24 weeks, patients will benefit from increased convenience and comfort," said Kamel Besseghir, CEO of Debiopharm S.A. "Furthermore, upon approval, our newly built production line will be ready to manufacture the drug for worldwide distribution."

The MAA for Decapeptyl(R) 6 month formulation is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of triptorelin.

About Decapeptyl(R)

Triptorelin was licensed-in from Tulane University in 1982. Debiopharm developed and submitted a 1- and 3-month sustained release formulation of triptorelin pamoate in Europe and
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
4. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
5. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
6. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
7. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
8. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
9. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, ... device company, announced that,the two-year data from ... Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will be presented today ... study examined the safety and efficacy of ...
... 26, 2007 /PRNewswire-FirstCall/ --,Australian drug development company ... randomised Phase II clinical,trial in patients with ... compared to irinotecan which is,considered to be ... colorectal,cancer. This announcement is being made at ...
Cached Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 2Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 4Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 5Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 6Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 7
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Teens who are sensitive ... likely to develop emotional symptoms such as anxiety and ... as these that may exacerbate issues teens experience after ... and in making decisions about when to return to ... these athletes," study authors Lisa Koehl and Dong Han, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Men who have a vasectomy ... a new study suggests. But the risk is ... involved with the study said more research is needed ... For the study, Harvard researchers analyzed data from ... 24 years, starting in 1986. During that time, 6,023 ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... Emergency Medical Service (EMS) responders felt better prepared to ... tactical training according to a new study in the ... the first study to specifically examine the EMS provider ... a shooter has not yet been neutralized or working ... such as the Columbine High School shooting, the Virginia ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Active shooter training increases comfort level of emergency responders 2
... associated with Alzheimer,s and mad cow disease, turns out ... paper published in Nature Chemical Biology , Frederic ... Universiteit Brussel describe that certain mutations of p53, an ... a way that the proteins start to aggregate. This ...
... 29 (HealthDay News) -- Dangerous methicillin-resistant staphylococcus aureus, or MRSA, ... this seasonal increase is more common in children than adults, ... analysis of MRSA cases that occurred at Rhode Island Hospital, ... children,s infections were higher in the third and fourth quarters ...
... application provided by the UK Resuscitation Council performed significantly ... did not, according to a study in the April ... approximately 30,000 people in the UK have an unexpected ... resuscitation research, survival rates for adults suffering a cardiac ...
... that liver transplant recipients who quit smoking have a ... keep smoking. In fact, SRMs were identified in 13.5% ... higher risk of malignancy in this study. Full findings ... Transplantation , a journal of the American Association for ...
... News) -- Death rates among teens and young adults aged 15 ... 4 years in many countries, says a new study that ... of researchers that analyzed the causes and patterns of death among ... 2004 also found that death rates among young males aged 15 ...
... Severely obese men and women who have bariatric surgery may ... much of their pre-surgery risk for experiencing disabling migraines, researchers ... a small study of obese patients with a history of ... roughly 66 pounds by the half-year point following either laparoscopic ...
Cached Medicine News:Health News:Cancer is a p53 protein aggregation disease 2Health News:MRSA Infections May Vary by Season 2Health News:Free phone app helped doctors perform better in simulated cardiac emergency 2Health News:Smoking in combination with immunosuppression poses greater risk for transplant-related carcinoma 2Health News:Death Rates of Children, Young Adults Show Reversal 2Health News:Weight-Loss Surgery May Cut Migraine Pain in Obese Patients 2Health News:Weight-Loss Surgery May Cut Migraine Pain in Obese Patients 3
... CC 527 is an assayed quality control material ... electrolyte, and CO-Oximeter instrumentation. It is for specific ... and hemoglobin fractions (280, 288, and 270) and ... 527 may also be used on the IRMA ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
For the qualitative detection of igG antibodies specific to Helicobacter pylori in human serum, plasma and whole blood specimens...
Medicine Products: